Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1985 2
1986 1
1988 1
1990 2
1993 2
1994 2
1998 3
2002 3
2005 1
2008 4
2009 1
2010 1
2011 2
2012 1
2014 3
2015 1
2017 1
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Ganapathy T, Radhakrishnan R, Sakshi S, Martin S. Ganapathy T, et al. Cancer Immunol Immunother. 2023 Feb;72(2):277-286. doi: 10.1007/s00262-022-03260-y. Epub 2022 Aug 12. Cancer Immunol Immunother. 2023. PMID: 35960333 Free PMC article. Review.
The HLA independent, multivalent, versatile and systemic anti-tumor immunity increases the desirability of gammadelta T cells as an alternate chassis for CAR. Indeed, CD19 gammadelta CAR T cell therapy to treat advanced lymphoma reached a milestone with the fast tra …
The HLA independent, multivalent, versatile and systemic anti-tumor immunity increases the desirability of gammadelta T cells as an alternat …
Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Rapoport AP, et al. Bone Marrow Transplant. 2002 Feb;29(4):303-12. doi: 10.1038/sj.bmt.1703363. Bone Marrow Transplant. 2002. PMID: 11896427 Free PMC article.
Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas.
Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, El-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A. Castagna L, et al. Bone Marrow Transplant. 2014 Dec;49(12):1475-80. doi: 10.1038/bmt.2014.197. Epub 2014 Sep 15. Bone Marrow Transplant. 2014. PMID: 25222502
Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. ...T-repleted Haploidentical tra …
Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem …
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N. Bouabdallah K, et al. Ann Oncol. 2015 Jan;26(1):193-198. doi: 10.1093/annonc/mdu503. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361987 Free article. Clinical Trial.
Our aim was to evaluate the safety of (90)Y-Ibritumomab tiuxetan in association with such a regimen in a prospective multicenter phase II trial. PATIENTS AND METHODS: Thirty-one patients with advanced lymphoma from five distinct institutions were included between Fe …
Our aim was to evaluate the safety of (90)Y-Ibritumomab tiuxetan in association with such a regimen in a prospective multicenter phase II tr …
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers ME, O'Donnell P, Sandmaier BM, Storb RF, Gopal AK. Ram R, et al. Biol Blood Marrow Transplant. 2011 Oct;17(10):1537-45. doi: 10.1016/j.bbmt.2011.03.010. Epub 2011 Apr 12. Biol Blood Marrow Transplant. 2011. PMID: 21536145 Free PMC article. Clinical Trial.
Reduced-intensity conditioning (RIC) before allogeneic hematopoietic cell transplantation (HCT) is increasingly used as a potentially curative option for patients with advanced lymphoma; however, relapse remains a major challenge. Unfortunately, little data are avai …
Reduced-intensity conditioning (RIC) before allogeneic hematopoietic cell transplantation (HCT) is increasingly used as a potentially curati …
Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era.
Holubar SD, Dozois EJ, Loftus EV Jr, Teh SH, Benavente LA, Harmsen WS, Wolff BG, Cima RR, Larson DW. Holubar SD, et al. Inflamm Bowel Dis. 2011 Jul;17(7):1557-63. doi: 10.1002/ibd.21516. Epub 2010 Nov 4. Inflamm Bowel Dis. 2011. PMID: 21674712
Survival free of death from lymphoma at 1- and 5-years was 78% and 63%, respectively, and was associated with advanced lymphoma stage (P = 0.004). CONCLUSIONS: Diagnosis and treatment of primary intestinal lymphoma in patients with IBD can be challenging and require …
Survival free of death from lymphoma at 1- and 5-years was 78% and 63%, respectively, and was associated with advanced lymphoma …
Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
Montes de Oca C, Castagna L, De Philippis C, Bramanti S, Schiano JM, Pagliardini T, Collignon A, Harbi S, Mariotti J, Granata A, Maisano V, Furst S, Legrand F, Chabannon C, Carlo-Stella C, Santoro A, Blaise D, Devillier R. Montes de Oca C, et al. Biol Blood Marrow Transplant. 2020 Dec;26(12):2299-2305. doi: 10.1016/j.bbmt.2020.08.014. Epub 2020 Aug 19. Biol Blood Marrow Transplant. 2020. PMID: 32822845 Free article.
The aims of study were to retrospectively assess the toxicity and efficacy of haplo-SCT using nonmyeloablative conditioning in patients with advanced lymphoma. In total, 147 patients with advanced lymphoma at 2 partner institutions were included. ...
The aims of study were to retrospectively assess the toxicity and efficacy of haplo-SCT using nonmyeloablative conditioning in patients with …
Evaluation of Short-Term Efficacy of PD-1 Monoclonal Antibody Immunotherapy for Lymphoma by Positron Emission Tomography/Computed Tomography Imaging with Convolutional Neural Network Image Registration Algorithm.
Fang J, Chen Z. Fang J, et al. Contrast Media Mol Imaging. 2022 Aug 31;2022:1388517. doi: 10.1155/2022/1388517. eCollection 2022. Contrast Media Mol Imaging. 2022. PMID: 36105450 Free PMC article.
The objective of this study was to investigate the value of PET/CT imaging based on CNN image registration algorithm in evaluating the short-term efficacy of PD-1 monoclonal antibody immunotherapy for lymphoma. 36 patients with advanced lymphoma confirmed by histolo …
The objective of this study was to investigate the value of PET/CT imaging based on CNN image registration algorithm in evaluating the short …
Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study.
Murthy V, Thomas K, Foo K, Cunningham D, Johnson B, Norman A, Horwich A. Murthy V, et al. Clin Lymphoma Myeloma. 2008 Aug;8(4):241-5. doi: 10.3816/CLM.2008.n.032. Clin Lymphoma Myeloma. 2008. PMID: 18765312 Clinical Trial.
PURPOSE: To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from advanced lymphoma. PATIENTS AND METHODS: A total of 36 patients (47 sites), received 4 Gy in 2 fractions to the lymphoma with …
PURPOSE: To confirm the efficacy of low-dose involved-field radiation therapy (LD-IFRT) as palliative treatment in patients symptomatic from …
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Armand P, et al. Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008. Biol Blood Marrow Transplant. 2008. PMID: 18342784 Free PMC article.
We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan. ...
We retrospectively analyzed the outcomes of 87 patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer …
35 results